GlaxoSmithKline (GSK) Given Overweight Rating at Barclays
GlaxoSmithKline (LON:GSK)‘s stock had its “overweight” rating reiterated by Barclays in a research report issued on Monday.
A number of other equities research analysts have also weighed in on the company. Jefferies Financial Group set a GBX 1,775 ($23.12) price objective on GlaxoSmithKline and gave the stock a “buy” rating in a research report on Thursday, August 16th. Societe Generale set a GBX 1,000 ($13.03) price objective on GlaxoSmithKline and gave the stock a “sell” rating in a research report on Monday, September 10th. Shore Capital restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, September 10th. Berenberg Bank restated a “buy” rating and set a GBX 1,790 ($23.32) price objective on shares of GlaxoSmithKline in a research report on Thursday, August 23rd. Finally, JPMorgan Chase & Co. set a GBX 1,600 ($20.84) price objective on GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, twelve have issued a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of GBX 1,539.86 ($20.06).
Shares of GSK stock opened at GBX 1,535.20 ($20.00) on Monday. GlaxoSmithKline has a twelve month low of GBX 1,235.20 ($16.09) and a twelve month high of GBX 1,724.50 ($22.46).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: What is the NASDAQ Stock Market?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.